Immunology Leads Shire's 2017 Sales Growth With Addition Of HAE Portfolio

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Immunology portfolio yielded 14% sales growth in 2017, led by growing subcutaneous immunoglobulins and a still-rising HAE franchise. Dry eye drug Xiidra was another 2017 growth catalyst.

Flemming Ornskov
Shire CEO Flemming Ornskov • Source: Source: Shire PLC

Calling 2018 a year that will be focused on commercial execution, targeted manufacturing infrastructure investment as well as the potential split of its rare disease and neuroscience units into separate businesses, Shire PLC CEO Flemming Ornskov pointed to immunology as a growth-leader for the Dublin-headquartered firm as it shifts focus away from a hectic business development pace in recent years.

During Shire's fourth quarter and full-year 2017 earnings call on Feb. 14, Ornskov noted that immunology provided the main impetus...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Nancy Tests SPARC-1036

Nancy tests Jira ticket SPARC-1036: Make anchor link work on initial page load

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch

 
• By Alexandra Shimmings

Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.    

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.